A review of emerging factor XI inhibitors.
Sandra ElsheikhNicola TidburyGregory Y H LipPublished in: Expert opinion on emerging drugs (2023)
Evidence suggests that FXI inhibition presents a promising drug target for novel anticoagulation therapies. The FXIa inhibitors in development have advantages over DOACs with lower renal clearance and long half-lives. Overall, FXI inhibition presents a promising target, it is likely that the clinical use of FXIa inhibitors is on the horizon.